Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
Date
2011Author
Waddell, T.Kotsori, A.
Constantinidou, Anastasia
Yousaf, N.
Ashley, Sue
Parton, M.
Allen, M.
Starling, N.
Papadopoulos, P.
O'Brien, M.
Smith, I. E.
Johnston, S. L.
Source
British journal of cancerVolume
104Issue
11Pages
1675-1679Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
BACKGROUND: Recent UK clinical guidance advises against continuing trastuzumab (T) beyond disease progression (PD) in the absence of brain metastases in patients with HER-2 positive (+ ve) advanced breast cancer. We have retrospectively evaluated the outcome of patients with HER-2 + ve locally advanced (LA) or metastatic breast cancer (MBC) who continued T beyond PD, treated in our unit. METHODS: All HER-2+ ve patients on our prospectively maintained database with LA or MBC who received T beyond PD after adjuvant or one line of T for advanced disease were assessed for response and outcome. From the timepoint of T continuation beyond PD, we calculated the overall disease control rate, time to progression (TTP), and overall survival (OS). RESULTS: One hundred and fourteen patients with HER-2 + ve LA or MBC treated with T beyond PD were identified. The main site of disease was visceral in 84 (74%) patients. Seventy-six (66%) had one line of chemotherapy before continuation of T beyond PD and 21 (19%) had two or more. Post-progression, 66 (58%) received T combined with chemotherapy. Of the 93 (82%) patients with documented clinical or radiological response evaluation, 67 (59%) were considered as having stable disease or better. The median TTP was 24 weeks (95% CI: 21-28) and the median OS was 19 months (95% CI: 12-24). CONCLUSION: Our results from an unselected group of patients provide additional evidence that continuation of T beyond PD is of clinical benefit. © 2011 Cancer Research UK.